Diabetes Treatment and Management has 529 eligible papers in the latest 30-day evidence window, up 32% from the prior window, with representative work spanning Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus; ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study; The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
Diabetes Treatment and Management shows 529 eligible recent papers and 528 commentary-ready papers in the current 30-day window, compared with 402 eligible papers in the prior window. The strongest evidence comes from 1 visible topic cluster and 8 representative papers. Several representative papers may be preprints, so this brief treats them as emerging signals rather than settled consensus.
Diabetes Treatment and Management recorded 529 eligible papers in the latest 30-day window, compared with 402 in the prior 30-day window, making the current snapshot up 32% from the prior window.
529 recent vs 402 prior eligible papersDiabetes Treatment and Management contributes 529 eligible recent papers, including 528 papers with abstracts available for commentary.
529 papers in the leading clusterThe representative set includes Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus; ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study; The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms; The SGLT2 inhibitor gap: why are we missing opportunities in primary care?; and other recent papers. These papers anchor the page's claims and keep the brief tied to visible evidence.
8 representative papersDiabetes Treatment and Management accounts for 529 eligible recent papers, including 528 commentary-ready papers in this evidence window.
529 recent eligible papersThe selected papers cover Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus; ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study; The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms; The SGLT2 inhibitor gap: why are we missing opportunities in primary care?.
8 representative papersA recent paper from International Journal of Molecular Sciences in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Italian Journal of Medicine in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Annual Review of Nutrition in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from British Journal of General Practice in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Diabetes Obesity and Metabolism in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Pharmaceutics in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Drug Metabolism Reviews in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Neurological Sciences in the Diabetes Treatment and Management evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.